source
- US ‘eroding’ lead in rare diseases a matter of national security: ReportA Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allow…BioSpace · 6d ago↗ source
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…BioPharma Dive · 6d ago↗ source
- 2026 IPO stock tracker: How newly public biotechs are performingBioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.